Treatment-related osteoporosis in men with prostate cancer.

  title={Treatment-related osteoporosis in men with prostate cancer.},
  author={Matthew Raymond Smith},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  volume={12 20 Pt 2},
The intended therapeutic effect of gonadotropin-releasing hormone (GnRH) agonists is hypogonadism, a major cause of acquired osteoporosis in men. Consistent with this observation, GnRH agonists increase bone turnover and decrease bone mineral density, a surrogate for fracture risk. Large claims-based analyses and other retrospective studies provide compelling evidence that GnRH agonists increase risk of clinical fractures. Estrogens play a central role in homeostasis of the normal male skeleton… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
21 Citations
49 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 21 extracted citations


Publications referenced by this paper.
Showing 1-10 of 49 references

Endocrine profiles during administrationof the newnonsteroidal antiandrogen Casodex in prostate cancer

  • J Verhelst, L Denis, P VanVliet
  • Clin Endocrinol ( Oxf )
  • 2004

Similar Papers

Loading similar papers…